Fulgent Genetics (FLGT)

• Market cap: $561M
• 1 day: -2.19%
• 5 days: -5.90%
• 1 month: 6.13%
• 3 months: -16.56%
• 6 months: -8.53%
• Year to date: -37.38%
• 1 year: -35.94%
• 5 years: 31.56%
• 10 years: 99.78%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Employees: 1,012

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

14,043% more call options, than puts

Call options by funds: $44.4M | Put options by funds: $314K

40% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 25

14% more capital invested

Capital invested by funds: $307M [Q2] → $350M (+$42.7M) [Q3]

6% more funds holding

Funds holding: 172 [Q2] → 182 (+10) [Q3]

0.83% more ownership

Funds ownership: 52.28% [Q2] → 53.12% (+0.83%) [Q3]

19% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 58

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $22 20% upside
• Avg. target: $22 20% upside
• High target: $22 20% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Piper Sandler David Westenberg 69% 1-year accuracy 27 / 39 met price target

20% upside $22

Neutral Maintained

11 Nov 2024